Detection of antibodies to the Epstein-Barr virus nuclear antigens in the sera from patients with systemic lupus erythematosus

Kitagawa, Harukazu; Iho, Sumiko; Yokochi, Takashi; Hoshino, Takashi

doi:10.1016/0165-2478(88)90037-5

Cited by 37 publications

(21 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we reasoned that looking for some viral ‘footprints’ in SLE patients could give a basis for further prospective studies. Previous reports demonstrated the higher prevalence or higher titers of some antiviral antibodies in SLE patients in comparison with a normal healthy population [6, 12, 32, 33, 34]. Our study confirms these data and first shows that, as antiviral antibodies do not parallel total immunoglobulin levels, it does not seem that they merely reflect a polyclonal B activation.…”

Section: Discussionsupporting

confidence: 91%

Correlation between Cytomegalovirus Infection and Raynaud’s Phenomenon in Lupus nephritis

Stratta

Canavese²,

Ciccone³

et al. 1999

Nephron

View full text Add to dashboard Cite

Relationships between viruses and autoimmune diseases such as systemic lupus erythematosus (SLE) are still elusive. Recent reports demonstrated the association of some viral infections with peculiar clinical events in the general population, such as cytomegalovirus (CMV) with arterial damage and Parvovirus B19 (PV-B19) with hematologic abnormalities. We planned to look for this kind of viral imprinting in SLE, hypothesizing that traces of specific features of some viral infections might be found in some subsets of seropositive SLE patients. In 60 SLE patients recruited at our nephrologic center, serology for CMV, PV-B19, Epstein-Barr virus viral capsid antigen (EBV-VCA), Epstein-Barr nuclear antigen (EBNA) and Epstein-Barr virus early antigen (EBV-EA) was performed. χ² and ANOVA were employed to compare the frequency and titers of antiviral antibodies in SLE patients with groups of transplant, hemodialysis and blood donor subjects. χ², Fisher’s test, Bonferroni and Scheffe’s test were employed to compare the different biochemical/clinical features between seropositive and seronegative SLE patients. Univariate and multivariate analysis (logistic regression models) were employed to evaluate the odds ratio (OR) of different risk factors for vascular events (including Raynaud’s phenomenon, deep venous thrombosis) and hematologic abnormalities (including severe anemia, leukopenia and thrombocytopenia). Anti-CMV (82%), anti-PV-B19 (60%), anti-EBV-VCA (92%) and EBV-EA (45%) IgG antibodies were frequent in SLE, with higher prevalence in comparison with the blood donor group and higher titers in comparison with transplant and hemodialysis groups. CMV seropositivity was a highly significant risk factor for Raynaud’s phenomenon (OR +α in univariate and multivariate analysis = 13.51 using a correction of 0.5 in case of a zero event), but not for venous vascular events (OR = 1.31). An increased though not significant risk factor was found for antiphospholipid antibodies (OR = 2.71, p = 0.19), while the presence of nephrotic syndrome during the follow-up was a significant protective factor (OR = 0.15, p = 0.035). There was no significantly increased OR for PV-B19 seropositivity in cases with severe anemia (OR = 2.09, p = 0.29). No significant associations were found with the status of EBV reactivation. In conclusion, our results support the hypothesis that viral infection may imprint the course of SLE leading to specific clinical subsets (i.e. CMV and ‘vascular’ SLE, with more frequent Raynaud’s phenomenon and a less frequent typical histological renal picture responsible for nephrotic syndrome). Further prospective studies are justified to validate these correlations, mainly dealing with associations between acute viral infections and vascular events, thus eventually leading to a better understanding of mutual relationships between viruses and SLE.

show abstract

Section: Discussionsupporting

confidence: 91%

Correlation between Cytomegalovirus Infection and Raynaud’s Phenomenon in Lupus nephritis

Stratta

Canavese²,

Ciccone³

et al. 1999

Nephron

View full text Add to dashboard Cite

show abstract

“…The immunoblot analysis also showed the detection of EBNA-1 was more frequent and stronger than that of EBNA-2, compared to the other groups. In contrast to hemodialysis patients, it has been reported that high levels of anti-EBNA-2 antibody were detected in patients with RA and SLE [33]. Anti-EBNA-1 antibody usually appeared at a later phase of EBV infection than anti-EBNA-2 antibody.…”

Section: Discussionmentioning

confidence: 87%

Epstein-Barr Virus Activity in Patients on Chronic Hemodialysis

Yamamoto

Nakajima²,

Yamamoto³

et al. 1995

Nephron

View full text Add to dashboard Cite

Patients with uremia are susceptible to viral infections, especially to Epstein-Barr virus (EBV). Sixty-one patients with end-stage renal diseases on chronic hemodialysis (HD), 14 patients with impaired renal function (CRF), and 27 healthy controls were studied with regard to EBV infection. Uremic patients (HD and CRF) had a significantly higher incidence of EBV infection and higher titers of anti-EBV VCA-IgG antibody than healthy controls. The anti-EBNA-1 titer was significantly higher in patients whose dialysis period was more than 3 months than in whom the dialysis period was 3 months or less. Immunoblotting analysis also showed stronger EBNA-1 signals in hemodialysis patients than EBNA-2, which was strongly detected in the CRF group and in healthy controls. EBV DNA was detected by Southern blot hybridization after PCR amplification of peripheral leukocytes, and occurred at a greater incidence in hemodialysis patients than in the other groups. Taken together, these results demonstrated that hemodialysis patients had persistent EBV infection.

show abstract

“…In SLE, 238 Tsai/Chiang/Kao/Hsieh Epstein-Barr Virus and Systemic Lupus erythematosus polyclonal B activation might play an important role in the pathogenic mechanism of the disease process, and abnor mal expansion of the autoreactive B cell population induced by viral infection like EBV might lead to autoimmune reac tions. Antibodies against specific EBV nuclear antigens have been related to certain autoimmune diseases such as rheumatoid arthritis, sjogren syndrome, and SLE [23][24][25], In addition, antibodies to early diffuse antigens have also been found to be present in a high percentage of SLE and mixed connective tissue disease patients [26]. The possible participation of HCMV and EBV in the pathogenesis of JRA has been evaluated with detection of DNA by PCR; however, the results were still not conclusive [27,28], Our study was performed to explore the possible relationship between EBV-and CMV-positive rates of leukocytes and the pathogenesis of JRA and childhood SLE.…”

Section: Discussionmentioning

confidence: 99%

Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus

Tsai

Chiang

Kao

et al. 1995

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The role of infectious agents in the pathogenesis of autoimmune diseases has long been a matter of debate. This study investigated the possible role of Epstein-Barr virus (EBV) and human cytomegalovirus (HCMV) infections in the pathogenesis of autoimmune diseases by an attempt to demonstrate the presence of the viral genome in the leukocyte of 21 juvenile rheumatoid arthritis (JRA) patients, 20 childhood-onset systemic lupus erythematosus (SLE) patients, and 20 age-matched normals, using polymerase chain reaction (PCR) and DNA probes. The results showed: (1) there was no difference in serum IgG anti-EBV antibody titers among three groups; (2) the EBV PCR-positive rates for JRA and SLE patients and normal controls were 5% (1/21), 10 (2/20), and 0% (0/20), respectively; (3) the HCMV PCR-positive rates for JRA and SLE patients and normal controls were 33% (7/21), 25 (5/20), and 10% (2/20), respectively, and (4) the HCMV-positive rate was 25% for JRA patients with steroid treatment and 33% for those without steroid treatment. It is, therefore, concluded that: (1) the data do not support the participation of EBV and HCMV in the pathogenesis of childhood-onset SLE and JRA; (2) steroid therapy does not increase the frequency of HCMV infection in JRA patients, and (3) immunoincompetence might be one of the major factors contributing to increased susceptibility to HCMV infection in JRA and SLE patients.

show abstract

Detection of antibodies to the Epstein-Barr virus nuclear antigens in the sera from patients with systemic lupus erythematosus

Cited by 37 publications

References 7 publications

Correlation between Cytomegalovirus Infection and Raynaud’s Phenomenon in Lupus nephritis

Correlation between Cytomegalovirus Infection and Raynaud’s Phenomenon in Lupus nephritis

Epstein-Barr Virus Activity in Patients on Chronic Hemodialysis

Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus

Contact Info

Product

Resources

About